About Integral membrane protein GPR137B
Integral membrane protein GPR137B (GPR137B) is a protein
from Homo sapiens identified by UniProt accession
O60478, 399 residues long.
MolForge cross-references it against 0 known binders and
38 disease associations.
Target properties
| Protein name | Integral membrane protein GPR137B |
| UniProt accession | O60478 |
| Gene | GPR137B |
| Organism | Homo sapiens |
| Length | 399 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (38)
Diseases linked to this target (Open Targets).
- C-reactive protein measurement · score 0.41
- cortical surface area measurement · score 0.30
- diastolic blood pressure · score 0.28
- brain measurement · score 0.24
- blood protein measurement · score 0.13
- vertebral joint disease · score 0.07
- ovarian carcinoma · score 0.03
- Acute hepatic failure · score 0.02
- juvenile idiopathic arthritis · score 0.01
- atherosclerosis · score 0.01
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-O60478-F1 | alphafold | PREDICTED | 68.92 | — |
Amino-acid sequence (399 residues)
MRPERPRPRG SAPGPMETPP WDPARNDSLP PTLTPAVPPY VKLGLTVVYT VFYALLFVFI YVQLWLVLRY RHKRLSYQSV FLFLCLFWAS LRTVLFSFYF KDFVAANSLS PFVFWLLYCF PVCLQFFTLT LMNLYFTQVI FKAKSKYSPE LLKYRLPLYL ASLFISLVFL LVNLTCAVLV KTGNWERKVI VSVRVAINDT LFVLCAVSLS ICLYKISKMS LANIYLESKG SSVCQVTAIG VTVILLYTSR ACYNLFILSF SQNKSVHSFD YDWYNVSDQA DLKNQLGDAG YVLFGVVLFV WELLPTTLVV YFFRVRNPTK DLTNPGMVPS HGFSPRSYFF DNPRRYDSDD DLAWNIAPQG LQGGFAPDYY DWGQQTNSFL AQAGTLQDST LDPDKPSLG
Explore Integral membrane protein GPR137B with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets